Description
Release form
Film-coated tablets.
Packing
28 pcs.
Pharmacological action
Zanidip-Recordati – a blocker of “slow” calcium channels. Lercanidipine is a racemic mixture of right- (R) and left-handed (S) stereoisomers, a derivative of 1,4-dihydropyridine, which is capable of selectively blocking the flow of calcium ions into the cells of the vascular wall, heart cells, and smooth muscle cells. The mechanism of the hypotensive effect is due to the direct relaxing effect on vascular smooth muscle cells. It has a prolonged antihypertensive effect. The therapeutic effect is achieved 5-7 hours after ingestion and its duration persists for a day (24 hours). Due to its high selectivity to vascular smooth muscle cells, there is no negative inotropic effect. Lercanidipine is a metabolically neutral drug and does not significantly affect the serum lipoproteins and apolipoproteins, and also does not change the lipid profile in patients with arterial hypertension.
Indications
Essential mild to moderate hypertension.
Contraindications
Hypersensitivity,
decompensated heart failure, unstable angina pectoris, aortic stenosis, recent myocardial infarction (within 1 month),
severe hepatic impairment, renal impairment (CK less than 12 ml / min women, s) not using reliable contraception, pregnancy, lactation,
childhood and adolescence (up to 18 years).
For LF containing lactose (optional): lactose intolerance, galactosemia, glucose / galactose malabsorption syndrome.
Caution. Renal and / or liver failure, CVD (without pacemaker), coronary heart disease, LV dysfunction, advanced age.
Special instructions
During treatment, care must be taken when driving vehicles and engaging in potentially hazardous activities that require increased concentration of attention and speed of psychomotor reactions.
Composition
1 tablet contains:
Active substances: lercanidipine 10 mg.
Excipients: lactose monohydrate – 30 mg, MCC – 39 mg sodium carboxymethyl starch 15, 5 mg povidone K30 – 4.5 mg magnesium stearate – 1 mg.
Shell (dosage of 10 mg): Opadry yellow (OY-SR-6497) – 3 mg (hypromellose, talc, titanium dioxide (E171), macrogol-6000, dye iron oxide yellow (E172).
Dosage and administration
Zanidip-Recordati is taken orally, in the morning, at least 15 minutes before meals, without chewing, with plenty of water, 10 mg once a day.
Dose may be increased to 20 mg (depending on individual effect). Increasing the dose to 20 mg is carried out 2 weeks after the start of the drug.
In case of mild or moderate renal or hepatic insufficiency, increase the dose to 20 mg per day with caution.
Side effects
WHO statistics: very often 1/10 appointments, often 1/100 appointments, not often 1/1000 appointments, rarely 1/10000 appointments, very rarely less than 1/10000 appointments.
From the nervous system: rarely – drowsiness infrequently – headache, dizziness
From the immune system: very rarely – increased sensitivity
From the cardiovascular system: not often – tachycardia, palpitations, flushing of blood to the skin of the face rarely – angina pectoris very rare – fainting, marked decrease in blood pressure, chest pain, myocardial infarction
From the digestive system: rarely – nausea, vomiting, diarrhea, abdominal pain , dyspepsia, very rarely – increased activity of liver enzymes (reversible)
From the skin: rarely – skin rash
From the musculoskeletal system: rarely – myalgia
From the urinary system: rarely – polyuria
General disorders and places s reactions: rarely – peripheral edema, rarely – fatigue, fatigue very rare – gingival hyperplasia.
Overdose
Symptoms: peripheral vasodilation with a marked decrease in blood pressure and reflex tachycardia, an increase in the frequency and duration of angina attacks, myocardial infarction.
Treatment: symptomatic therapy.
Storage conditions
At a temperature not exceeding 30 ° C. Keep out of reach of children.
Dosage form
tablet
Rekordati chemical and pharmaceutical industry, Italy
